Newsfile Corp
18 Nov 2026, 20:42 UTC · 2h ago
CADL INVESTORS: Securities Fraud Investigation by Block & Leviton Could Allow Candel Therapeutics Investors to Recover Losses
Impact · against what's priced in
Candel Therapeutics faces potential liquidity risks and legal headwinds following the announcement of a securities fraud investigation by Block & Leviton. This introduces a new risk factor regarding potential class action settlements and cash outflows.
- CADL−0.30
No priced-in read yet





